Companies rush to develop “utterly transformative” gene therapies

The approval of gene therapy for leukemia, expected in the next few months, will open the door to a radically new class of cancer treatments.Companies and universities are racing to develop these new therapies, which re-engineer and turbocharge millions of a patient’s own immune cells, turning them into cancer killers that researchers call a “living drug.”